105 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
10 May 24
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
7:01am
to low 20 percent on net sales; and full reimbursement of future KIO-301 research and development expenses.
Reported quantitative functional MRI … million in cash and cash equivalents plus $1.8 million in research and development incentive tax credits and $0.2 million in collaboration receivables from
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Mar 24
Results of Operations and Financial Condition
7:03am
, and commercial milestones; tiered royalties of up to low 20’s on net sales; and reimbursement of KIO-301 research and development expenses.
Completed … million and the Company believes this will fund operations through 2026.
In 2023, research and development expenses were $4.0 million, net of $1.7 million
8-K
EX-99.1
3j20k98twytor4gs
12 Feb 24
Regulation FD Disclosure
5:23pm
8-K
EX-99.1
nh0q9gtiwjdfbzh 5u5
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
nokd og62
9 Nov 23
Results of Operations and Financial Condition
7:01am
8-K
EX-99.1
1f99qcdb4ioz0a xmin
8 Aug 23
Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
7:14am
8-K
3lywo38yrl
1 Aug 23
Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
7:00am
8-K
EX-99.1
9wod7sn fpnh1
1 Aug 23
Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
7:00am
8-K
EX-10.1
oh5nz6vs dsc2w
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
424B1
os4gco31akn7ltfi5
2 Jun 23
Prospectus with pricing info
5:08pm
8-K
EX-99.1
bz74pj vbq2
9 May 23
Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
7:02am